Dr. Iris Nira Smith shares her experience with the pudendal nerve conduction test and how she handles living with pudendal neuralgia.

Jessica Strasburg, MD discusses the most common causes and symptoms of pudendal neuralgia and what treatment options are available.

Eating ultraprocessed foods for more than 20% of your daily calorie intake every day could set you on the road to cognitive decline, a new study revealed. We all know eating ultraprocessed foods that make our lives easier -- such as prepackaged soups, sauces, frozen pizza and ready-to-eat meals -- isn't good for our health. Nor is gobbling up all the pleasure foods that we love so much: hot dogs, sausages, burgers, french fries, sodas, cookies, cakes, candies, doughnuts and ice cream, to name…

Dr. Sharon Sutherland discusses the latest cervical cancer preventions, including HPV vaccination, cervical cancer screening options and drugs that suppress immune response.

Should physicians be prescribing hormone therapy (HT) to help prevent certain chronic health conditions for people who are post-menopausal? Holly Thacker, MD, FACP, director of Cleveland Clinic’s Center for Specialized Women’s Health, believes there may be a good case for doing so with some patients.The first steps, however, should be a physical exam, a careful assessment of when the patient entered menopause, and a conversation that explores the potential risks and benefits of hormone therapy,…

20 years after the Women's Health Initiative (WHI), women are still concerned about the risks of hormone therapy. Dr. Holly L. Thacker discusses how hormone therapy is still the most effective treatment for menopause symptoms, especially hot flashes and night sweats.

Dr. Sandra Darling shares 6 healthy lifestyle tips to stimulate and support the brain and help lower the risk of Alzheimer's disease and other types of dementia.

Speaking of Women's Health guest columnist, Cheryl Taylor RNFA at Cleveland Clinic, shares tips on how women can prepare for and recover from hip and knee replacement surgeries.

The U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. This marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata. Alopecia areata, commonly referred to as just alopecia, is an autoimmune disorder in which the body attacks its…

Speaking of Women's Health is proud to be awarded a Digital Health Award for their HerDesire.net educational initiative on low sex drive. the awards were judged by more than 100 experts, with over 1,000 entries, recognizing the BEST in digital health resources.

Dr. Irina Todorov discusses how human connection is important for one's health.

Speaking of Women's Health guest columnist Dr. Jessica Ruff shares how acupuncture can help reduce headaches.

Scientists still may not know the exact cause of fibromyalgia, but that hasn’t stopped them from developing treatments for the chronic pain associated with the condition. For years, all of those therapeutics have been of the pharmacological variety, with three drugs approved by the FDA since 2007. Now, however, patients will have a drug-free alternative to treat their fibromyalgia, as the agency issued a de novo clearance for a wearable neuromodulation system from NeuroMetrix designed to ease…

The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control. Mounjaro is a…

The American Heart Association published a 2020 scientific statement on cardiovascular disease risk for women transitioning through or experiencing menopause. The report reflects scientific evidence on menopause and cardiovascular risks, and this article reviews the statement with a focus on what is new and what is clinically important for healthcare providers treating this patient population.

On the 20th anniversary of the now infamous Women’s Health Initiative (WHI) study that brought the field of Hormone Replacement Therapy (HRT) to its knees, it is only fitting that we revisit the study and use science-backed information to emphasize the true outcome of the findings. Especially when two decades later women are still impacted by the aftershocks. Join Dr. Holly L. Thacker and Dr. Alexa Fiffick from the Cleveland Clinic's Center for Specialized Women’s Health, as they address the…

Dr. Alexa N. Fiffick discusses how headaches are more common in women. Two of the most common headache conditions are cervicogenic headache and migraine.

Dr. Holly L. Thacker shares seven ways women can help prevent osteoporosis and have strong, healthy bones.

Twenty years ago, the National Institutes of Health abruptly terminated research on the effect of hormone therapy on postmenopausal women. The decision resulted in a cascade of harm to millions who have undergone menopause in the United States. And it remains uncorrected two decades later. More than 1 billion people worldwide will be in menopause by 2025. Today, there are 55 million in the United States alone, nearly 75 percent of whom report not receiving support or treatment for its effects.…

The U.S. Food and Drug Administration approved a 0.5 mg/100 mg dose of TherapeuticsMD Inc.'s  Bijuva hormone therapy. This low-dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause, is 0.5 milligrams (mg) of estradiol and 100 mg of progesterone (0.5/100mg). In 2018, the FDA approved Bijuva for the treatment of moderate to severe vasomotor symptoms of menopause at the 1mg of estradiol and 100 mg of progesterone (1/100 mg) dose.To learn…